Related Experiment Videos
Myelodysplastic syndrome is not merely "preleukemia"
Maher Albitar1, Taghi Manshouri, Yu Shen
1Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston 77030-4095, USA. malbitar@mdanderson.org
Blood
|July 20, 2002
Summary
Myelodysplastic syndrome (MDS) is biologically distinct from acute myeloid leukemia (AML). Research shows MDS involves increased cell death, not just blast percentage, necessitating targeted therapies.
Area of Science:
- Hematology
- Oncology
- Cell Biology
Background:
- Myelodysplastic syndrome (MDS) is characterized by ineffective hematopoiesis.
- Significant biologic and clinical differences exist between MDS and acute myeloid leukemia (AML).
Purpose of the Study:
- To compare the clinical and biologic characteristics of MDS and AML patients.
- To elucidate the distinct biological features of MDS compared to AML.
Main Methods:
- Studied a cohort of 802 patients (279 MDS, 523 AML) with complete clinical and cytogenetic data.
- Analyzed apoptosis, angiogenesis, proliferation, and growth factors in a subgroup of patients.
- Utilized cell sorting and loss of heterozygosity to assess leukemic cell differentiation.
Main Results:
- MDS is a discrete entity from AML, primarily characterized by increased apoptosis in hematopoietic cells.
- Leukemic cells in MDS patients can differentiate into mature myeloid cells and monocytes.
- An overlap exists between AML and MDS when defined by blast percentage (20-30%).
Conclusions:
- MDS is biologically and clinically different from AML and should not be considered an early phase of AML.
- MDS requires definition based on its biology, not solely blast percentage.
- Therapeutic strategies should target the specific biologic abnormalities of MDS.